Executives disclosed new directions in neurodegenerative disease testing and low-volume sample collection for high-volume testing.

The Helsinki-based company said it will use the funds to support further development of its AI-based digital pathology platform.

The firm touted a new clinical chemistry and immunoassay instrument and brain health assays in its diagnostics business during a call with investors on Friday morning.

A panel discussion at the Association for Diagnostics & Laboratory Medicine this week tackled questions around coding, reimbursement, and regulation of AI-based tests.

NEW YORK – As the liquid biopsy space has exploded in recent years, clinical laboratories are struggling to find sufficient staff to oversee and run these assays. Staffing is a problem for the ...

The company reported Q2 2026 revenue of $3.73 billion compared to $3.53 billion in the year-ago period, beating Wall Street's consensus estimate of $3.71 billion.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

The company is now guiding to 2026 revenue of between $770 million and $790 million compared to a previous guidance of between $860 million and $880 million.

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

The firm increased its full-year guidance to a new range of $1.34 billion to 1.36 billion from a previous range of $1.30 billion to $1.32 billion.